Premium
Influence of Pharmacy Benefit Practices on Off‐Label Dispensing of Drugs in the United States
Author(s) -
Teagarden J R,
Dreitlein W B,
Kourlas H,
Nichols L
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.367
Subject(s) - pharmacy , clinical pharmacology , food and drug administration , statutory law , medicine , pharmacology , off label use , drug , alternative medicine , drug labeling , business , family medicine , political science , law , pathology
Statutory limits on the US Food and Drug Administration (FDA) authority to control the clinical use of drugs after approval raise concerns about unapproved uses (known as “off‐label uses”). However, where the FDA cannot check off‐label uses, various components of the US health‐care system can. Pharmacy benefit management is one of these components. We describe how pharmacy benefit management influences off‐label use through coverage policies and clinical management practices. Clinical Pharmacology & Therapeutics (2012); 91 5, 943–945. doi: 10.1038/clpt.2011.367